484 related articles for article (PubMed ID: 26131743)
21. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
Schmidt T; Paust HJ; Krebs CF; Turner JE; Kaffke A; Bennstein SB; Koyro T; Peters A; Velden J; Hünemörder S; Haag F; Steinmetz OM; Mittrücker HW; Stahl RA; Panzer U
Arthritis Rheumatol; 2015 Feb; 67(2):475-87. PubMed ID: 25385550
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of FoxO3a expression through PI3K/Akt pathway attenuates the progression of lupus nephritis in MRL/lpr mice.
Zhao C; Gu Y; Chen L; Su X
Int Immunopharmacol; 2020 Dec; 89(Pt A):107027. PubMed ID: 33039957
[TBL] [Abstract][Full Text] [Related]
23. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
Patole PS; Gröne HJ; Segerer S; Ciubar R; Belemezova E; Henger A; Kretzler M; Schlöndorff D; Anders HJ
J Am Soc Nephrol; 2005 May; 16(5):1326-38. PubMed ID: 15772251
[TBL] [Abstract][Full Text] [Related]
24. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
25. Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus.
Liang B; Kashgarian MJ; Sharpe AH; Mamula MJ
J Immunol; 2000 Sep; 165(6):3436-43. PubMed ID: 10975864
[TBL] [Abstract][Full Text] [Related]
26. CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice.
Wu X; Guo J; Ding R; Lv B; Bi L
Acta Histochem; 2015 Oct; 117(8):732-7. PubMed ID: 26456520
[TBL] [Abstract][Full Text] [Related]
27. Increased responsiveness of B. cells in the murine MRL/lpr model of lupus nephritis to interleukin-1 beta.
Lebedeva TV; Singh AK
J Am Soc Nephrol; 1995 Jan; 5(7):1530-4. PubMed ID: 7703391
[TBL] [Abstract][Full Text] [Related]
28. Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus.
Mackern-Oberti JP; Obreque J; Méndez GP; Llanos C; Kalergis AM
Clin Exp Immunol; 2015 Oct; 182(1):1-13. PubMed ID: 26095291
[TBL] [Abstract][Full Text] [Related]
29. B10 Cells Ameliorate the Progression of Lupus Nephritis by Attenuating Glomerular Endothelial Cell Injury.
Yu M; Song Y; Zhu MX; Liang W; Long Q; Ding PW; Xie Y; Liao YH; Yuan J
Cell Physiol Biochem; 2015; 36(6):2161-9. PubMed ID: 26279423
[TBL] [Abstract][Full Text] [Related]
30. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice.
Matsumoto K; Watanabe N; Akikusa B; Kurasawa K; Matsumura R; Saito Y; Iwamoto I; Saito T
Arthritis Rheum; 2003 Feb; 48(2):486-94. PubMed ID: 12571859
[TBL] [Abstract][Full Text] [Related]
31. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models.
Sugahara K; Maeda Y; Shimano K; Murase M; Mochiduki S; Takemoto K; Kakimoto T; Utsumi H; Oshita K; Kataoka H
J Immunol Res; 2019; 2019():5821589. PubMed ID: 31930150
[TBL] [Abstract][Full Text] [Related]
32. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
Pérez de Lema G; Lucio-Cazaña FJ; Molina A; Luckow B; Schmid H; de Wit C; Moreno-Manzano V; Banas B; Mampaso F; Schlöndorff D
Kidney Int; 2004 Sep; 66(3):1018-28. PubMed ID: 15327395
[TBL] [Abstract][Full Text] [Related]
33. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
Watanabe H; Garnier G; Circolo A; Wetsel RA; Ruiz P; Holers VM; Boackle SA; Colten HR; Gilkeson GS
J Immunol; 2000 Jan; 164(2):786-94. PubMed ID: 10623824
[TBL] [Abstract][Full Text] [Related]
34. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B
J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157
[TBL] [Abstract][Full Text] [Related]
35. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
Lu LD; Stump KL; Wallace NH; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Mason JL; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
J Immunol; 2011 Oct; 187(7):3840-53. PubMed ID: 21880982
[TBL] [Abstract][Full Text] [Related]
36. Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice.
Tada Y; Nagasawa K; Ho A; Morito F; Koarada S; Ushiyama O; Suzuki N; Ohta A; Mak TW
J Immunol; 1999 Sep; 163(6):3153-9. PubMed ID: 10477582
[TBL] [Abstract][Full Text] [Related]
37. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
Mannoor K; Matejuk A; Xu Y; Beardall M; Chen C
J Immunol; 2012 Apr; 188(8):3628-38. PubMed ID: 22407922
[TBL] [Abstract][Full Text] [Related]
38. Lupus nephritis in the absence of renal major histocompatibility complex class I and class II molecules.
Mukherjee R; Zhang Z; Zhong R; Yin ZQ; Roopenian DC; Jevnikar AM
J Am Soc Nephrol; 1996 Nov; 7(11):2445-52. PubMed ID: 8959638
[TBL] [Abstract][Full Text] [Related]
39. IL-33 neutralization suppresses lupus disease in lupus-prone mice.
Li P; Lin W; Zheng X
Inflammation; 2014 Jun; 37(3):824-32. PubMed ID: 24398614
[TBL] [Abstract][Full Text] [Related]
40. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]